Research Topics
Genomes and Genes
| Severine VermeireSummaryAffiliation: Katholieke Universiteit Leuven Country: Belgium Publications
| Collaborators
|
Detail Information
Publications
Role of biomarkers in the diagnosis of inflammatory bowel diseaseSeverine Vermeire
University Hospital Leuven, Department of Gastroenterology, Herestraat 49, 3000 Leuven, Belgium 32 16 34 42 25 32 16 34 43 99
Expert Opin Med Diagn 1:481-8. 2007..Nevertheless, these markers are often negative in this setting. The interest in antimicrobial and antiglycan antibodies has recently been increased as they have shown to act as surrogate markers of complicated aggressive disease...
Towards a novel molecular classification of IBDSeverine Vermeire
Department of Gastroenterology, Leuven University Hospitals, Leuven, Belgium
Dig Dis 30:425-7. 2012..Only then could the value of molecular markers to predict the speed of progression be fully explored in prospective studies...
Effects of haptoglobin polymorphisms and deficiency on susceptibility to inflammatory bowel disease and on severity of murine colitisL Marquez
Department of Gastroenterology, Gasthuisberg Hospital, KU Leuven, Belgium
Gut 61:528-34. 2012..Its gene (16q22) harbours a common polymorphism with two different alleles: Hp1 and Hp2. Genotype Hp22 has been shown to be over-represented in different immune diseases. Results in Crohn's disease (CD) are contradictory...
The role of C-reactive protein as an inflammatory marker in gastrointestinal diseasesSeverine Vermeire
Department of Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Nat Clin Pract Gastroenterol Hepatol 2:580-6. 2005..Until there are more data, the use of CRP and of other biomarkers should be seen as an additional tool that aids clinical observation and physical examination, but that cannot replace it...
The use of immunosuppressive drugs in IBD: RAND or random choice?S Vermeire
University Hospital Gasthuisberg, Division of Gastroenterology, Herestraat 49, 3000 Leuven, Belgium
Dig Liver Dis 37:391-3. 2005
Current status of genetics research in inflammatory bowel diseaseS Vermeire
University Hospital Gasthuisberg Leuven, Division of Gastroenterology Herestraat, Leuven 49 3000, Belgium
Genes Immun 6:637-45. 2005..Overall, it is anticipated that genetic markers in the future will be implemented in an integrated molecular diagnostic and prognostic approach of our patients...
To what extent are genetics clinically useful?Severine Vermeire
Gastroenterology Department, University Hospitals Leuven, Leuven, Belgium
Best Pract Res Clin Gastroenterol 25:S8-14. 2011..Efforts to predict disease course and response to therapy have shown interesting results...
Association of organic cation transporter risk haplotype with perianal penetrating Crohn's disease but not with susceptibility to IBDSeverine Vermeire
Department of Gastroenterology, UZ Gasthuisberg, Leuven, Belgium
Gastroenterology 129:1845-53. 2005..We studied mutation prevalence, assessed phenotypic expression, and performed conditional analysis to examine evidence for gene-gene interactions...
Review article: Altering the natural history of Crohn's disease--evidence for and against current therapiesS Vermeire
Department of Gastroenterology, University Hospital Leuven, Leuven, Belgium
Aliment Pharmacol Ther 25:3-12. 2007..Major advances in treatment options over the past years have made our treatment goals more ambitious and modification of the natural course has become the ultimate endpoint...
Laboratory markers in IBD: useful, magic, or unnecessary toys?S Vermeire
Department of Internal Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
Gut 55:426-31. 2006..They are however not magic and until more data become available, the use of CRP and other laboratory markers should be seen as an additive tool to clinical observation and physical examination rather than a replacement...
Serum sickness, encephalitis and other complications of anti-cytokine therapySeverine Vermeire
University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium
Best Pract Res Clin Gastroenterol 23:101-12. 2009..We discuss the safety aspects of the biological agents in this chapter and, where available, give ways to prevent and/or treat them...
The changing face of treatment for Crohn's diseaseS Vermeire
Department of Medicine, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
Br J Surg 93:385-6. 2006
Inflammatory bowel disease and colitis: new concepts from the bench and the clinicSeverine Vermeire
Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium
Curr Opin Gastroenterol 27:32-7. 2011..The previous 18 months have shown important progress in unravelling the causes of inflammatory bowel disease (IBD) and in improving its management for the patients...
The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised studySeverine Vermeire
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Gut 60:1068-75. 2011..This first-in-human study of a monoclonal antibody to MAdCAM, PF-00547,659, aimed to explore the safety and preliminary efficacy of this gut-specific mechanism in ulcerative colitis...
Review article: genetic susceptibility and application of genetic testing in clinical management of inflammatory bowel diseaseS Vermeire
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Aliment Pharmacol Ther 24:2-10. 2006..In the future, it is anticipated that genetic markers will be implemented in an integrated molecular diagnostic and prognostic approach to managing our patients...
Perianal Crohn's disease: classification and clinical evaluationS Vermeire
Division of Gastroenterology, University of Leuven, Herestraat 49, 3000 Leuven, Belgium
Dig Liver Dis 39:959-62. 2007..This review analyses and discusses current classifications of any perianal form of Crohn's disease...
Role of genetics in prediction of disease course and response to therapySeverine Vermeire
Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
World J Gastroenterol 16:2609-15. 2010..Nevertheless, the importance and necessity of pharmacogenetic studies will increase further as more therapeutic classes are being developed...
Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severitySeverine Vermeire
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Clin Gastroenterol Hepatol 8:357-63. 2010..We investigated whether a simpler tool, the Harvey-Bradshaw Index, was equally effective in assessing disease severity...
(Auto)antibodies in inflammatory bowel diseasesSeverine Vermeire
Department of Gastroenterology, University Hospitals Leuven Belgium, UZ Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
Gastroenterol Clin North Am 37:429-38, vii. 2008..However, currently, they have no place in the diagnostic work up. Their real promise may lie in their use as surrogate markers of complicated aggressive disease as shown in various retrospective studies, but prospective data are lacking...
NOD2/CARD15: relevance in clinical practiceSeverine Vermeire
Gastroenterology Unit, University Hospital Gasthuisberg Leuven, Herestraat 49, 3000 Leuven, Belgium
Best Pract Res Clin Gastroenterol 18:569-75. 2004..Finally, screening unaffected relatives of CD patients is not recommended until preventive strategies are available...
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trialGert Van Assche
Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
Gastroenterology 134:1861-8. 2008..We aimed to study the influence of immunosuppressives discontinuation in patients in remission with combination therapy in an open-label, randomized, controlled trial...
Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel diseaseLiesbet Henckaerts
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Gut 56:1536-42. 2007..Materials and..
Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatmentIngrid Arijs
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Am J Gastroenterol 106:748-61. 2011..This migration is regulated by cell adhesion molecules (CAMs), and selective antimigration therapies have been developed. This study investigated the effect of infliximab therapy on the mucosal gene expression of CAMs in IBD...
Clustering of (auto)immune diseases with early-onset and complicated inflammatory bowel diseaseMirjam Bueno de Mesquita
Department of Paediatric Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
Eur J Pediatr 168:575-83. 2009..6%, respectively, p<0.0001) and more often had concomitant immune-mediated diseases and a trend for more seroreactivity towards ASCA...
Pancreatic autoantibodies in inflammatory bowel diseaseSofie Joossens
Department of Gastroenterology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium
Inflamm Bowel Dis 10:771-7. 2004..We observed two main staining patterns, both of which were present in IBD and were associated with specific phenotypes of the disease...
Transmission of CARD15 (NOD2) variants within families of patients with inflammatory bowel diseaseNele Esters
Department of Gastroenterology, UZ Gasthuisberg, Leuven, Belgium
Am J Gastroenterol 99:299-305. 2004..Since nothing is known about the transmission of these variants within families, this was the subject of our study in Flemish patients with inflammatory bowel disease (IBD) and their healthy relatives...
Genetic variants in autophagy-related genes and granuloma formation in a cohort of surgically treated Crohn's disease patientsMarko Brinar
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
J Crohns Colitis 6:43-50. 2012..Genetic variants in autophagy genes IRGM and ATG16L1 have been associated with susceptibility to Crohn's disease. We therefore investigated whether variants in autophagy genes contribute to granuloma formation...
Cystic fibrosis transmembrane conductance regulator gene polymorphisms in patients with primary sclerosing cholangitisLiesbet Henckaerts
Department of Gastroenterology, University Hospital Gasthuisberg, Catholic University of Leuven, Herestraat 49, B 3000 Leuven, Belgium
J Hepatol 50:150-7. 2009..The histological features in the liver of PSC patients are similar to those observed in cystic fibrosis (CF). Our aim was to study whether variants in the CFTR gene are associated with the occurrence and/or evolution of PSC...
Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatmentIngrid Arijs
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
PLoS ONE 4:e7984. 2009..We investigated the impact of anti-inflammatory therapy with infliximab on the mucosal gene expression of AMPs in IBD...
Immunosuppression in inflammatory bowel disease: traditional, biological or both?Gert Van Assche
Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
Curr Opin Gastroenterol 25:323-8. 2009..To focus on the emerging clinical evidence for the use of traditional immunosuppressives and biologicals in the treatment of inflammatory bowel disease...
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's diseaseFilip Baert
Department of Gastroenterology, H Hartziekenhuis Roeselare Menen vzw, Roeselare, Belgium
Gastroenterology 138:463-8; quiz e10-1. 2010..Few prospective data are available to support the clinical relevance of mucosal healing in patients with Crohn's disease. This study examined whether complete healing, determined by endoscopy, predicts a better outcome in Crohn's disease...
Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's diseaseIngrid Arijs
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Inflamm Bowel Dis 16:2090-8. 2010..However, a subset of patients shows incomplete or no response to this agent. In this study we investigated whether we could identify a mucosal gene panel to predict (non)response to IFX in CD...
Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseasesMarie Pierik
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Inflamm Bowel Dis 12:1-8. 2006..This is underscored by the finding of the association between CARD15 variants and Crohn's disease (CD) and D299G in Toll-like receptor (TLR) 4 and IBD. Our aims were to study nonsynonymous polymorphisms in other TLR genes in IBD...
Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healingTalat Bessissow
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Am J Gastroenterol 107:1684-92. 2012..We aimed to investigate the predictive role of serologic and histologic markers on disease relapse in UC patients with endoscopically inactive disease...
Treatment of severe steroid refractory ulcerative colitisGert Van Assche
Division of Gastroenterology, University of Leuven Hospitals, Herestraat 49, Leuven, Belgium
World J Gastroenterol 14:5508-11. 2008..Therefore, patients not responding to these agents within 5-7 d should be considered for colectomy and responders should be closely monitored for infections...
New serological markers in inflammatory bowel disease are associated with complicated disease behaviourMarc Ferrante
Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
Gut 56:1394-403. 2007....
Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case seriesMarc Ferrante
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Inflamm Bowel Dis 16:243-9. 2010..In case reports, thiopurine analogs and infliximab (IFX) have been proposed as effective therapy in this setting. We analyzed the long-term efficacy of IFX in Belgian patients with refractory pouch complications...
Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's diseaseMatthias Jürgens
Department of Gastroenterology, UZ Gasthuisberg, Leuven, Belgium
Clin Gastroenterol Hepatol 9:421-7.e1. 2011..C-reactive protein (CRP) is a marker used to identify and follow individuals with CD. We analyzed changes in levels of CRP in a large cohort of patients with CD undergoing treatment with infliximab...
Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's diseaseFabian Schnitzler
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Inflamm Bowel Dis 15:1295-301. 2009..Infliximab (IFX) treatment induces mucosal healing (MH) in patients with Crohn's disease (CD) but the impact of MH on the long-term outcome of IFX treatment in CD is still debated...
The role of vascular endothelial growth factor (VEGF) in inflammatory bowel diseaseMarc Ferrante
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Inflamm Bowel Dis 12:870-8. 2006..Moreover, serum VEGF (sVEGF) levels are increased in IBD and correlate with disease activity. Both VEGF expression and sVEGF levels may be influenced by VEGF gene polymorphisms...
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's diseaseSeverine Vermeire
Department of Internal Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Gut 56:1226-31. 2007..Concomitant use of immunosuppressives (IS) reduces the risk of ATI formation...
Decreased mucosal sulfide detoxification is related to an impaired butyrate oxidation in ulcerative colitisVicky De Preter
Translational Research Center for Gastrointestinal Disorders TARGID and Leuven Food Science and Nutrition Research Centre LFoRCe, University Hospital Gasthuisberg, KULeuven, Leuven, Belgium
Inflamm Bowel Dis 18:2371-80. 2012..In this study we measured colonic mucosal TST enzyme activity and gene expression in UC and controls. In addition, the influence of sulfides on butyrate oxidation was evaluated...
C-reactive protein as a marker for inflammatory bowel diseaseSeverine Vermeire
Department of Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Inflamm Bowel Dis 10:661-5. 2004..However, whether we need to include CRP as an inclusion criterion for future trials with biologicals is still a matter of debate...
Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's diseaseKonstantinos Karmiris
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Gastroenterology 137:1628-40. 2009....
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's diseaseSeverine Vermeire
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Am J Gastroenterol 97:2357-63. 2002..CONCLUSIONS: In this large cohort of infliximab-treated CD patients, young age, Crohn's colitis, and concomitant immunosuppressive treatment were identified as independent variables favoring short-term response to infliximab...
Tumor necrosis factor receptor gene polymorphisms in Crohn's disease: association with clinical phenotypesKevin A Waschke
Department of Medicine, Division of Gastroenterology, McGill University Inflammatory Bowel Disease Program, Montreal, Canada
Am J Gastroenterol 100:1126-33. 2005..Our purpose was to determine whether single nucleotide polymorphisms (SNPs) in the TNF receptors confer susceptibility to Crohn's disease and whether they are associated with clinical phenotype...
Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn's diseaseMarie Joossens
Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Inflamm Bowel Dis 16:58-67. 2010..Our aim was to test whether a combination of CD-associated genes involved in innate immunity and/or antibody responses to microbial antigens may be valuable in identifying healthy relatives at risk...
Genetic risk profiling and prediction of disease course in Crohn's disease patientsLiesbet Henckaerts
Department of Medicine, Gastroenterology Section, Catholic University of Leuven, Leuven, Belgium
Clin Gastroenterol Hepatol 7:972-980.e2. 2009..We examined the influence of recently discovered CD-associated susceptibility loci on changes in disease behavior and evaluated whether a genetic risk model for disease progression could be generated...
Mucosal healing and anti TNFs in IBDGert Van Assche
Department of Gastroenterology, Leuven University Hospitals, 49 Herestraat, Leuven, Belgium
Curr Drug Targets 11:227-33. 2010..In clinical practice assessing mucosal healing should be considered in patients with persistent symptoms despite adequate therapy and when treatment discontinuation is being considered...
Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximabZhe Li
Laboratory of Experimental Immunology, Catholic University of Leuven, Leuven, Belgium
Inflamm Bowel Dis 16:1299-310. 2010..Therefore, we investigated the effect of infliximab (IFX) therapy on Forkhead box protein3 (Foxp3) T cells in blood and intestinal mucosa from Crohn's disease (CD) and ulcerative colitis (UC)...
Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitisJoris Arts
Department of Internal Medicine, University Hospital, Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium
Inflamm Bowel Dis 10:73-8. 2004..CONCLUSIONS: CSA is an effective treatment of the majority of patients with severe attacks of UC, although the toxicity and even mortality associated with its use necessitates careful evaluation, selection, and follow-up...
Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trialPaul Rutgeerts
Department of Gastroenterology, University Hospital Gasthuisberg, 3000 Leuven, Belgium
Gastroenterology 128:856-61. 2005..We investigated the efficacy and safety of ornidazole, a nitroimidazole antibiotic, for the prevention of clinical recurrence of Crohn's disease after curative ileocolonic resection in a placebo-controlled double-blind clinical trial...
Seroreactivity against glycolytic enzymes in inflammatory bowel diseaseNathalie Vermeulen
Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium
Inflamm Bowel Dis 17:557-64. 2011..Patients with inflammatory bowel disease (IBD) carry autoantibodies such as perinuclear antineutrophil cytoplasmic antibodies. The aim of the current study was to further characterize the immune reactivity in IBD...
Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapyFabian Schnitzler
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Inflamm Bowel Dis 17:1846-54. 2011..Infliximab (IFX) and adalimumab (ADA) are attractive treatment options in patients with inflammatory bowel disease (IBD) also during pregnancy but there is still limited data on the benefit/risk profile of IFX and ADA during pregnancy...
Interleukin-15 receptor α expression in inflammatory bowel disease patients before and after normalization of inflammation with infliximabClémentine Perrier
Department of Gastroenterology, Translational Research Centre for Gastrointestinal Disorders TARGID, KU Leuven, Leuven, Belgium
Immunology 138:47-56. 2013..Expression is localized in B cells, suggesting that IL-15 regulates B-cell functions during bowel inflammation. No change in release of sIL-15Rα is observed in patients treated with IFX...
Genomic copy number determines functional expression of {beta}-defensin 2 in airway epithelial cells and associates with chronic obstructive pulmonary diseaseWim Janssens
Department of Human Genetics, Katholieke Universiteit Leuven, Gasthuisberg O and N1 602, Herestraat 49, B 3000, Leuven, Belgium
Am J Respir Crit Care Med 182:163-9. 2010..Objectives: We investigated whether genomic copy number variations of the beta-defensin gene cluster have a functional role in airway epithelial cells and associate with the presence of COPD...
Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort studyChristine Breynaert
Division of Gastroenterology, Leuven University Hospitals, Leuven, Belgium
Am J Gastroenterol 106:778-85. 2011..The primary end point was the incidence of infusion reactions in both groups...
Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relativesMarie Joossens
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Gut 60:631-7. 2011..Whether dysbiosis is present in relatives of patients CD was also examined...
Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort studySeverine Vermeire
Gastroenterology Department, University Hospital Gasthiuisberg, Leuven, Belgium
Gastroenterology 125:32-9. 2003..Two patients developed drug-induced lupus erythematosus. Antinuclear antibodies were associated with the female sex and skin manifestations...
Predictors of early response to infliximab in patients with ulcerative colitisMarc Ferrante
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Inflamm Bowel Dis 13:123-8. 2007..Our objective is to report the outcome of infliximab (IFX) in ulcerative colitis (UC) patients from a single center and to identify predictors of early clinical response...
Small bowel review: Diseases of the small intestineAlan B R Thomson
Nutrition and Metabolism Group, Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
Dig Dis Sci 48:1582-99. 2003
Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictorsTibor Hlavaty
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Inflamm Bowel Dis 13:372-9. 2007..Predictors of response could improve selection of patients with a higher probability of favorable outcomes and could improve the safety profile. We aimed to develop a predictive model for the response to infliximab in CD...
Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trialGeert R D'Haens
Department of Gastroenterology, Leuven University Hospitals, Leuven, Belgium
Gastroenterology 135:1123-9. 2008..Goal: We sought to examine whether metronidazole for 3 months together with azathioprine (AZA) for 12 months is superior to metronidazole alone to reduce recurrence of postoperative CD in "high-risk" patients...
Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitisDavid N Moskovitz
Department of Internal Medicine, University Hospital, Gasthuisberg Herestraat, Leuven, Belgium
Clin Gastroenterol Hepatol 4:760-5. 2006..CONCLUSIONS: CSA is an effective short- to medium-term treatment for patients with severe UC but at 7 years, 88% of patients will require a colectomy. Azathioprine-naive patients have better outcomes...
Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease)Marc Ferrante
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Curr Gastroenterol Rep 11:504-8. 2009..Finally, it remains unclear if and when a biologic agent can be stopped in patients with long-standing remission...
Long-term outcome after infliximab for refractory ulcerative colitisMarc Ferrante
Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
J Crohns Colitis 2:219-25. 2008..We investigated long-term outcome including colectomy rates in outpatients treated with IFX for refractory UC in a single referral centre, and evaluated if predictors could be identified...
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's diseaseFilip Baert
Department of Internal Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
N Engl J Med 348:601-8. 2003..Concomitant immunosuppressive therapy reduces the magnitude of the immunogenic response...
Optimizing anti-TNF treatment in inflammatory bowel diseasePaul Rutgeerts
Department of Medicine, Division of Gastroenterology, University of Leuven, Belgium
Gastroenterology 126:1593-610. 2004..Other adverse events associated with anti-TNF strategies are demyelinating disease and worsening of congestive heart failure. Malignancy rates in patients treated with anti-TNF strategies do not seem to be increased...
NOD2/CARD15 does not influence response to infliximab in Crohn's diseaseSeverine Vermeire
Department of Gastroenterology, UZ Gasthuisberg, Leuven, Belgium
Gastroenterology 123:106-11. 2002..It is not clear which factors influence treatment outcome. We assessed whether variants in NOD2/CARD15 are predictive for differences in clinical response...
Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitisMarc Ferrante
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Inflamm Bowel Dis 14:20-8. 2008..During the course of their disease, about 30% of patients with ulcerative colitis (UC) will undergo proctocolectomy with ileal pouch-anal anastomosis (IPAA). We evaluated the outcome of IPAA in a Belgian referral center...
Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn's diseaseTibor Hlavaty
University Hospital Gasthuisberg, Leuven, Belgium
Inflamm Bowel Dis 12:199-204. 2006..Whereas the validity and reproducibility of the IBDQ have been extensively studied, there are limited data on its short-term responsiveness and cutoff values for remission and partial clinical response...
Pharmacogenetics in inflammatory bowel diseaseMarie Pierik
Department of Gastro enterology, University of Hospital Gasthuisberg, Leuven, Belgium
World J Gastroenterol 12:3657-67. 2006..An effort should be made to collect genomic DNA from all patients enrolled in clinical drug trials after appropriate informed consent for pharmacogenetic studies...
Development of pouchitis following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis: A role for serological markers and microbial pattern recognition receptor genesMarc Ferrante
Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, B3000 Leuven, Belgium
J Crohns Colitis 2:142-51. 2008..We investigated the role of antimicrobial and antiglycan antibodies and polymorphisms in microbial pattern recognition receptor genes...
Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?Paul Rutgeerts
University Hospital Gasthuisberg, Department of Gastroenterology, Herestraat 49, Leuven 3052, Belgium
Gut 56:453-5. 2007..We propose that future studies should focus on healing and disease course as primary outcome measures...
Immunogenicity of infliximab: how to handle the problem?Filip Baert
Department of Gastroenterology, University Hospital Leuven, Herestraat 49, 3000 Leuven, Belgium
Acta Gastroenterol Belg 70:163-70. 2007..Antibody formation is associated with allergic reactions and loss of response...
Anti-alpha-enolase antibodies in patients with inflammatory Bowel diseaseNathalie Vermeulen
Department of Internal Medicine, University Hospital Leuven, Leuven, Belgium
Clin Chem 54:534-41. 2008..alpha-Enolase has been proposed as a target antigen in IBD. We evaluated the prevalence and diagnostic value of anti-alpha-enolase antibodies in IBD and related disorders...
Novel biological strategies in inflammatory bowel diseasesSeverine Vermeire
Department of Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Inflamm Bowel Dis 10:S44-51. 2004
The role of genetics in inflammatory bowel diseaseLiesbet Henckaerts
Department of Gastroenterology University Hospital Gasthuisberg, Leuven, Belgium
Curr Drug Targets 9:361-8. 2008..The optimal prediction of both disease behaviour and response to therapy might result from complex combinations of clinical, biochemical, serological and genetic factors...
The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipientsDirk R J Kuypers
Department of Nephrology and Renal Transplantation, Laboratory of Absorption and Digestion, University Hospitals Leuven, Belgium
Clin Pharmacol Ther 78:351-61. 2005....
Medical treatment of inflammatory bowel diseasesGert Van Assche
Division of Gastroenterology, University of Leuven, Leuven, Belgium
Curr Opin Gastroenterol 21:443-7. 2005..Despite the advent of the anti-TNF agent, infliximab, an important unmet medical need characterizes the medical treatment of inflammatory bowel diseases. This review aims to summarize recent progress in the field...
Crohn's disease and month of birthMarc Van Ranst
Laboratory of Clinical and Epidemiological Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium
Inflamm Bowel Dis 11:597-9. 2005..Some studies suggested an association between the month of birth and the later development of IBD. We studied this putative relationship in a large cohort of Belgian patients with Crohn's disease (CD)...
Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitisGert Van Assche
Department of Gastroenterology, University of Leuven, 49, Herestraat, Leuven 3000, Belgium
Gastroenterology 125:1025-31. 2003..Our single center, randomized, double-blind, controlled trial aimed to evaluate the additional clinical benefit of 4 mg/kg over 2 mg/kg IV cyclosporine in the acute treatment of severe UC...
Emerging biological treatments in inflammatory bowel diseasesGert Van Assche
Division of Gastroenterology, University of Leuven, Leuven, Belgium
Dig Dis 24:131-6. 2006..As illustrated by unexpected but devastating brain infections with anti-adhesion molecules, clinicians should be aware that the powerful immunomodulatory capacity of biologicals necessitates a rigorous safety follow-up...
Biological therapies for inflammatory bowel diseasesPaul Rutgeerts
Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
Gastroenterology 136:1182-97. 2009..The efficacy of each therapy must be shown in carefully designed clinical programs. Biological therapies carry a definite safety risk, so their place in treatment algorithms must be defined carefully...
The potential for disease modification in Crohn's diseaseG Van Assche
Department of Gastroenterology, University Hospital Leuven, 3000 Leuven, Belgium
Nat Rev Gastroenterol Hepatol 7:79-85. 2010....
Management of acute severe ulcerative colitisGert Van Assche
Division of Gastroenterology, Leuven University Hospitals, Leuven, Belgium
Gut 60:130-3. 2011..Whereas prolonged exposure to steroids predisposes to an increased rate of peri-operative complications it is still debated whether cyclosporine or infliximab increase peri-operative morbidity in ulcerative colitis...
Safety issues with biological therapies for inflammatory bowel diseaseGert Van Assche
Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
Curr Opin Gastroenterol 22:370-6. 2006..The purpose of this review is to summarize recent evidence describing specific complications associated with the use of biological therapy derived from controlled trials and from post-marketing surveillance...
Optimizing treatment of inflammatory bowel diseases with biologic agentsGert Van Assche
Division of Gastroenterology, University of Leuven, 49, Herestraat 3000 Leuven, Belgium
Curr Gastroenterol Rep 10:591-6. 2008....
Polymorphisms in innate immunity genes predispose to bacteremia and death in the medical intensive care unitLiesbet Henckaerts
Department of Medicine, Catholic University of Leuven, Leuven, Belgium
Crit Care Med 37:192-201, e1-3. 2009..Our aim was to study the influence of single nucleotide polymorphisms in selected genes involved in innate immunity on the development of bacteremia or risk of death in patients admitted to a medical intensive care unit...
CC-type chemokine receptor 5-Delta32 mutation protects against primary sclerosing cholangitisLiesbet Henckaerts
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
Inflamm Bowel Dis 12:272-7. 2006..We therefore investigated the role of the functional 32-bp deletion in this gene (CCR5-Delta32) with regard to susceptibility to PSC...
Contribution of genetic and environmental factors in the pathogenesis of Crohn's disease in a large family with multiple casesMarie Joossens
Department of Gastroenterology, University Hospital, Leuven, Belgium
Inflamm Bowel Dis 13:580-4. 2007..In this family the father developed Crohn's disease (CD) after moving from Morocco to Belgium and successively 4 of his 8 children subsequently developed CD. There was no previous history of familial CD...
Interassay and interobserver variability in the detection of anti-neutrophil cytoplasmic antibodies in patients with ulcerative colitisSofie Joossens
Department of Gastroenterology, University Hospital Gasthuisberg, KULeuven, Leuven, Belgium
Clin Chem 50:1422-5. 2004
Toll-like receptor 2 and Toll-like receptor 4 polymorphisms in invasive pneumococcal diseaseLeen Moens
Department of Laboratory Medicine, University Hospital Leuven, Centraal Dienstengebouw, Herestraat 49, B 3000 Leuven, Belgium
Microbes Infect 9:15-20. 2007..Studies have revealed associations between polymorphisms in TLRs and human diseases. The effect of polymorphisms in TLR2 and TLR4 in the human defense to S. pneumoniae has not been studied...
Small bowel review: Normal physiology, part 2Alan B R Thomson
Nutrition and Metabolism Group, Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
Dig Dis Sci 48:1565-81. 2003
